Intraplaque angiogenesis is associated with the occurrence of atherosclerotic plaque rupture. Cardiovascular molecular imaging can be used for the detection of rupture-prone plaques. Imaging with radiolabeled bevacizumab, a monoclonal anti-vascular endothelial growth factor (VEGF)-A, can depict VEGF levels corresponding to the angiogenic status in tumors. We determined the feasibility of 89 Zr-bevacizumab imaging for the detection of VEGF in carotid endarterectomy (CEA) specimens. Five CEA specimens were coincubated with 89 Zr-bevacizumab and aspecific 111 In-labeled IgG to determine the specificity of bevacizumab accumulation. In 11 CEA specimens, 89 Zr-bevacizumab micro-positron emission tomography (PET) was performed following 2 hours of incubation.
C ARDIOVASCULAR IMAGING is an invaluable tool for evaluating atherosclerosis and provides clinical information needed for assessment of plaque burden, decision making, and evaluation of therapeutic efforts. Conventional imaging modalities are able to detect anatomic abnormalities within the structure of the vessel wall and luminal stenosis. However, most cardiovascular events do not correlate with stenosis severity but with rupture in nonstenotic plaques. 1 Thus, the accurate detection of plaques that are prone to rupture will improve the identification of individuals with a higher risk of vascular complications. Molecular imaging can be applied for targeting and quantification of ongoing biologic processes in atherosclerotic plaques leading to plaque rupture.
Intraplaque release of vascular endothelial growth factor (VEGF) is known to be an important process linked to plaque vulnerability. 2 Both VEGF and local hypoxia result predominantly in chemotactic processes within plaques. This process leads to the formation of immature blood vessels and subsequent intraplaque hemorrhage, thereby causing plaque instability. Clinical detection of intraplaque concentration of VEGF may be used for the assessment of plaque vulnerability.
The role of molecular imaging techniques in the detection of angiogenesis has been widely investigated in animal and experimental human studies targeting different molecules such as VEGF, 3 VEGF receptors, 4 and integrins. 5 Radiolabeling of the humanized monoclonal antibody bevacizumab for targeting of all VEGF-A isoforms can provide a nuclear imaging tracer and can be used to quantify VEGF levels in tumors, 6 to show evidence of angiogenesis, and to monitor therapeutic efforts targeting VEGF. 7, 8 Previously, we showed specific uptake of 89 Zrbevacizumab in a high-VEGF-secreting human SKOV-3 ovarian tumor xenograft in mice. 3 Angiogenesis imaging in patients with melanoma lesions demonstrated a strong correlation between semiquantitative 111 In-bevacizumab uptake and VEGF expression in tumor. 6 In this study, we investigated whether 89 Zr-bevacizumab VEGF imaging is feasible to detect VEGF in human carotid endarterectomy (CEA) specimens. We applied a method for ex vivo nuclear imaging of human CEA specimens that was recently developed by our group and takes advantage of high-resolution small-animal positron emission tomography (PET) technology in the visualization of molecular and cellular processes within atherosclerotic plaques. 9
Materials and Methods

Study Design and Specimens
This study was designed according to previous work by our group that demonstrated the feasibility of ex vivo molecular imaging of CEA specimens after incubation in a solution containing tracer followed by high-resolution microPET scan to visualize tracer uptake with great detail. The study was approved by the institutional ethics review board of the University Medical Center Groningen, Groningen, the Netherlands. Eleven CEA specimens were included from 11 patients who underwent CEA because of significant symptomatic carotid artery stenosis between June 2009 and August 2010. Risk factors and diagnostic data for individual patients are shown in Table 1 . The samples contained the carotid bifurcation, the distal segment of common carotid artery, and proximal segments of both the internal and external carotid arteries. Excised nonatherosclerotic renal artery obtained from a patient undergoing a kidney transplantation procedure was used as a negative control.
MicroPET Procedure
Bevacizumab (Avastin, 25 mg/mL; Roche, Mijdrecht, the Netherlands) conjugation and labeling with 89 Zr (half-life 5 3.27 days), from IBA Molecular, was performed as described previously. 10 For the preparation of incubation buffer, 89 Zrbevacizumab (6.9 6 4.0 MBq, 30 mg) was diluted in 10 mL phosphate-buffered saline (PBS). Immediately after excision, the specimens were transported under sterile conditions and subsequently incubated with 89 Zr-bevacizumab for 2 hours at room temperature. Before the microPET procedure, the plaques were flushed three to five times with PBS and fixed in a humid box to prevent dehydration. All specimens were fixed on a bed and scanned using a microPET focus 220 camera (Siemens Preclinical Solutions, Knoxville, TN) for 30 minutes. Thereafter, a micro-computed tomographic (CT) scan was performed using a microCAT II system (Siemens Preclinical Solutions) using the same fixed bed so that the stereotactic position was maintained. MicroPET images were corrected for scatter and reconstructed applying an iterative reconstruction algorithm (two-dimensional ordered subset expectation maximization [OSEM 2D]).
Determination of Specific Uptake
111 In (Covidien, Petten, the Netherlands) -labeled human IgG (Sanquin, Amsterdam, the Netherlands) was used as an aspecific control antibody as described previously. 10 A mixed dose of 89 Zr-bevacizumab and 111 In-IgG (5 6 0.5 MBq, 0.3 mL diluted in 10 mL PBS was prepared, and five control specimens were incubated. After 2 hours, specimens were washed with PBS and were counted in a calibrated well-type LKB-1282-Compu-gamma-system (LKB Wallac, Turku, Finland) using a dual-isotope counting program for both isotopes. The overlap of 89 Zr counts in 111 In channel was corrected. The activities of 89 Zr and 111 In were calculated as percent incubation dose per gram of tissue (%Inc/g).
Immunohistochemistry
After the scan, specimens were oriented on a flat surface and were serially cross-sectioned in 4 mm slices and numbered from proximal to distal. The sections were formalin fixed, paraffin embedded, and sectioned at 5 mm. The tissue slides were blocked with 0.3% H 2 O 2 , followed by blocking endogenous avidin and biotin (SP-2001, Vector Laboratories, Burlingame, CA), and were incubated with rabbit anti-VEGF antibody A-20 (diluted 1:50; Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hour at room temperature. Subsequently, the slides were incubated with biotinylated goat antirabbit antibody (diluted 1:300; DAKO), followed by ABC Elite (diluted 1:100; DAKO). Antibody detection was performed with the diaminobenzidine (DAB) kit (DAKO). The sections were counterstained with hematoxylin for 2 minutes. In five sections, macrophage content was evaluated by CD68 immunostaining and antibody was detected with the DAB kit to discover colocalization between VEGF and macrophage presence. All sections were examined on a blind basis using a light microscope with the 403 objective.
The level of VEGF staining was scored from 0 to 3, determined by semiquantitative combined assessment of the percentage of stained cells and the staining intensity as described before. 11 CD68 staining was categorized semiquantitatively according to a highly used and reproducible method as described previously. 9 
Data Analysis
Because of the short time difference between incubation and scanning, radioactive decay was considered negligible for both 89 Zr and 111 In. MicroPET and microCT images were registered using AMIDE software (version 0.9.1, Stanford University), and a whole-specimen three-dimensional region of interest (ROI) was drawn manually in microCT images and was applied to microPET images. The mean %Inc/g in total specimen was calculated. The maximal uptake of 89 Zr-bevacizumab within the specimen was determined and the hot spot was defined using a three-dimensional isocontour ROI with a threshold of 70% maximal uptake. %Inc/g in hot spot was calculated (%Inc/g hot spot ). To obtain a background value for 89 Zrbevacizumab uptake, %Inc/g was measured in a manually drawn ROI within a specimen adjacent to the hot spot. Segmental ROI were drawn manually in accordance with immunohistochemical slices to compare tracer accumulation with immunohistochemistry. In each segment, a segmental %Inc/g mean was calculated and the tissue to background ratio was calculated by dividing segmental %Inc/g mean by background tracer accumulation of the same specimen, as described above. Categorical measures of VEGF and CD68 staining were compared using the chisquare test.
Statistical Analysis
Quantitative results were shown as mean 6 SD. Regression analysis was used to determine relationships between mean %Inc/g in specimen and specimen size. %Inc/g mean and tissue to background ratio of 89 Zr-bevacizumab uptake in each segment were compared to semiquantitative measures of VEGF-A staining and the results were tested by use of Spearman correlation coefficients (r). Per specimen analysis was performed by calculating average VEGF-A staining scores, %Inc/g, and the tissue to background ratio of the stained segments of each specimen.
Results
Feasibility
The mean length of the specimens was 2.4 6 0.7 cm. The specimens were transported from the operating room to the laboratory within 10 minutes after excision. In all CEA specimens, clear 89 Zr-bevacizumab uptake within the arterial wall was seen ( Figure 1 ). 89 Zr-bevacizumab uptake in all plaques was heterogeneously distributed. The mean %Inc/g hot spot was 2.2 6 0.9, the mean %Inc/g in the specimen was 0.9 6 0.4 (ranging from 0.44 to 1.99), and the mean %Inc/g in the background was 0.6 6 0.3. The average hot spot to background ratio within the CEA specimens was 3.6 6 0.8. No correlation was found between plaque size and 89 Zr-bevacizumab uptake (r 5 .41; p 5 .2). The mean %Inc/g in the negative control arterial tissue was 0.18%.
Specific Uptake
In five specimens, the specificity of 89 Zr-bevacizumab uptake was evaluated. For this purpose, coincubation was performed using both 89 Zr-bevacizumab and control 111 In-IgG. Quantitative measurements of both tracers by gamma counter showed that 89 Zr-bevaciumab uptake was 10-fold higher when compared to the control 111 In-IgG (1.9 6 0.9 %Inc/g and 0.2 6 0.1 %Inc/g, respectively; p 5 .01).
VEGF Staining, Tracer Uptake, and Macrophage Content
VEGF staining was performed in 35 slices of the CEA specimens ( Figure 2 ). Segmental %Inc/g mean and tissue to background ratio in each group of VEGF staining are shown in Table 2 . In total stained segments, the segmental %Inc/g mean was 1.05 6 0.39 and the tissue to background ratio was 2.05 6 0.6. An association between VEGF score and segmental %Inc/g mean (r 5 .29, p , .05) and tissue to background ratio of 89 Zr-bevacizumab uptake (r 5 .74, p , .001) was determined by Spearman correlation analysis ( Figure 3A ). Per specimen analysis was performed in nine specimens. Average VEGF scores, %Inc/g, and the tissue to background ratio of each specimen are shown in Table 3 . Spearman correlation analysis showed an excellent correlation between average tissue to background ratio and average VEGF score (r 5 .91, p , .01, Figure 3B ); however, no correlation was found between average %Inc/g and average VEGF score in CEA specimens (data not shown).
To evaluate the cellular basis of VEGF release, CD68 staining was performed in eight sections and showed a colocalization between subendothelial macrophage content and VEGF staining (Figure 4) . The chi-square test showed that the sections did not differ in VEGF and CD68 staining scores (p 5 .45).
Discussion
In the present study, we showed for the first time the feasibility of ex vivo 89 Zr-bevacizumab VEGF imaging in human CEA specimens. Here we report the promising features of radiolabeled anti-VEGF PET in atherosclerotic plaques. Accumulation of the tracer was size independent and heterogeneously distributed within the plaque with a high signal to background ratio. The average mean %Inc/g in CEA specimens was five times higher than the mean %Inc/g in a normal artery. Moreover, a high specific uptake was demonstrated as we showed a 10-fold higher accumulation of 89 Zr-bevacizumab compared to control 111 In-IgG using dual-isotope gamma counting and sizeindependent uptake. Furthermore, we showed that the mean activity accumulation in the plaque correlates with the tissue VEGF abundance, determined by immunohistochemistry. Our finding suggests the possibility of designing further clinical studies to assess the role of a VEGF-targeting tracer to obtain PET images in stratifying the risk of patients with atherosclerotic disease.
[ 18 F]Fluorodeoxyglucose PET imaging has been proposed for detecting macrophage content and vulnerability in atherosclerotic plaques. 12 However, the fact that [ 18 F]FDG accumulates in any highly metabolizing cell results in suboptimal specificity in depicting vessel wall inflammation. 13 Detection of VEGF activation, a pathophysiologically relevant indicator of macrophages and an independent determinant of plaque vulnerability, might offer the opportunity to track both vessel wall inflammation and angiogenesis in atherosclerosis. This study has shown a colocalization and similar intensity scores of VEGF and CD68 (a marker of macrophages) in CEA specimens; however, in accordance with previous studies, VEGF was also abundant in areas with numerous smooth muscle cells and within extracellular matrix. 14 This result emphasizes the link between inflammation and angiogenesis in atherosclerotic plaques and raises the possibility that Figure 3 . A, The correlation between vascular endothelial growth factor (VEGF) score with segmental percent incubation dose per gram of tissue (%Inc/g mean ) (black bars; r 5 .29, p , .05) and segmental tissue to background ratio (dotted bars; r 5 .74, p , .001). B, Per specimen correlation between average tissue to background ratio and VEGF scores in the stained specimens (Spearman rank correlation). %Inc/g 5 percent incubation dose per gram of tissue; VEGF 5 vascular endothelial growth factor. VEGF score was determined according to semiquantitative combined assessment of the percentage of stained cells and the staining intensity as described in Kitamura and colleagues. 11 VEGF-targeted imaging could provide indirect information on plaque inflammation correlated to its vulnerability in vivo. The predictive role of 18 FDG PET or VEGFtargeted imaging with plaque vulnerability and rupture needs to be further investigated and compared.
Although it has been suggested by some studies that VEGF may also have a potential beneficial role in atherosclerotic disease through regeneration of endothelium and endothelial function improvement, 15 a large body of evidence underlines the substantial role of VEGF in the maintenance and destabilization of atherosclerotic plaques rather than its protective effects. 16 Thus, the ability to image VEGF within plaques by PET can offer a promising tool for evaluating vulnerability and monitoring therapeutic efforts aimed at stabilization of atherosclerotic plaques. In previous investigations, the value of radiolabeled bevacizumab imaging was shown in the detection of VEGF in VEGF-secreting tumors. 3, [6] [7] [8] Adequate preservation of binding affinity of 89 Zrlabeled bevacizumab was previously shown by our group using a VEGF-coated enzyme-linked immunosorbent assay (ELISA). 3 In vitro evaluation of binding affinity showed 54% 6 3.7% binding of 89 Zr-bevacizumab to VEGFcoated wells. Additions of 500-fold excess unlabeled bevacizumab for competition assay resulted in almost complete blocking of radiolabeled bevacizumab binding (, 5%, ranging from 1 to 4%) comparable to nonspecific binding of radiolabeled IgG (4-8%).
The specificity of radiolabeled bevacizumab uptake was previously shown in a study by our group on human tumor xenografts 3 and indicated VEGF-mediated 89 Zrbevacizumab uptake. To verify the specificity of 89 Zrbevacizumab uptake in CEA specimens, we were not able to execute the frequently used approach of blocking specimens using an excess of the unlabeled bevacizumab as it has been shown that administration of unlabeled bevacizumab could cause functional changes in tissue and influence the pathobiologic properties of CEA specimens. 17 In this study, instead, we coincubated the specimens in equal doses of 89 Zr-bevacizumab and aspecific 111 In-IgG as a control. Samples were counted for radioactivity by using a dual-isotope gamma-counting program in a calibrated well-type gamma counter, the same method used in a previous study by our group. 18, 19 The results showed 10-fold higher accumulation of 89 Zrbevacizumab than that of 111 In-IgG. Moreover, normal arterial tissue was incubated in 89 Zr-bevacizumab and showed five times less accumulation of bevacizumab, which further confirms the specificity of the tracer.
Another approach in visualization of the VEGF pathway and evaluation of angiogenesis is molecular imaging of VEGF receptor. In vivo imaging with radiolabeled VEGF 121 ( 64 Cu-DOTA-VEGF 121 ) has successfully demonstrated the ability to depict VEGF receptor in a mouse model of human glioblastoma tumor. 4 Recently, an easyto-label 68 Ga-labeled tracer, based on engineered singlechain VEGF, has been developed and showed promising characteristics for imaging VEGF receptor in angiogenic vasculature. 20 Given that the correlation between VEGF tissue concentration and VEGF receptor expression and the corresponding role of their levels in the progression of angiogenesis is not well determined, the two methods for imaging and quantification of VEGF and VEGF receptor can be complementary in evaluating angiogenesis in vivo. Although mean segmental %Inc/g mean and mean tissue to background ratio in different VEGF scores showed a trend to superior accumulation of 89 Zr-bevacizumab uptake in higher scores of VEGF (see Figure 3 ), there was a weak correlation between mean segmental %Inc/g mean and VEGF immunohistochemistry scores. Per specimen analysis also showed that despite an excellent correlation between mean tissue to background ratio in the stained sections, there was no association between average %Inc/g and average VEGF scores in the specimens. This may partially be explained by semiquantitative measurements of immunohistochemistry results. Moreover, VEGF staining shows cytoplasmic and macrophage-bound VEGF, although it is not very sensitive in accounting for the detection of VEGF secreted into the extracellular matrix. On the contrary, 89 Zr-bevacizumab has a high affinity to all VEGF-A isoforms, including those secreted into the extracellular matrix. To overcome this difference in targeting VEGF, we compared semiquantitative immunohistochemistry results to semiquantitative microPET measures of tissue to background ratio. The results showed a good correlation between segmental tissue to background ratio and VEGF staining level (Spearman r 5 .74) and specimen average tissue to background ratio and specimen average VEGF staining score (Spearman r 5 .91). A better correlation between VEGF scores with relative measures of 89 Zr-bevacizumab accumulation (tissue to background ratio) rather than absolute measures of tracer accumulation could also be explained by the fact that variability in the tracer dose in incubation buffer (6.4 6 4.0 MBq) can result in different accumulation of bevacizumab in normal tissue within the specimens. However, tissue to background ratio corrects the quantitative imaging data for possible variation in the pharmacokinetic behavior of 89 Zr-bevacizumab in normal tissue due to a wide range of tracer dose. In addition, the fact that segmental %Inc/g mean was compared to VEGF immunohistochemistry score on a 5 mm section of a 4 mm wide segment, which cannot represent total VEGF level within the segment, is an acknowledged limitation of this study. Tissue extract ELISA can provide more precise information on VEGF levels in corresponding segments of microPET images in future studies.
It has been reported in tumor xenografts that due to the long half-life of bevacizumab in blood (17-21 days) and its slow pharmacokinetics, the optimal imaging time, which provides the highest target to blood ratio, is 4 to 7 days after tracer injection. In our study, we targeted VEGF ex vivo; therefore, a long incubation time was not necessary. Future studies should be designed to determine the optimal imaging time point after tracer injection that provides the highest target to blood ratio in humans. Furthermore, future application of fluorescent or radiolabeled bevacizumab and other VEGF-targeted tracers in coronary artery disease requires a high target to heart uptake ratio. In previous work by our group, we observed a specific uptake value of 3.43% 6 0.99% in mouse heart 24 hours after injection, which rapidly declined over time (2.31% 6 0.93% at 72 hours and 2.11% 6 0.66 % at 168 hours). 3 In our study, the average %Inc/g hot spot of 89 Zrbevacizumab at 2 hours was 2.2 6 0.9. We predict an increase in plaque uptake of 89 Zr-bevacizumab over time, which remains high at 72 to 168 hours, with the same pattern that we observed in tumors. However, this prediction needs to be tested explicitly.
Given that bevacizumab is a recombinant humanized monoclonal antibody and species specific, it is not possible to investigate the role of 89 Zr-bevacizumab in viable rodent models of atherosclerosis, namely apolipoprotein Edeficient and low-density lipoprotein receptor-deficient mice. However, in a recent study on immunodeficient mice transplanted with human coronary artery tissue, it was shown that bevacizumab treatment ameliorates vascular remodeling through VEGF blockade. 21 89 Zr-bevacizumab imaging in this animal model can provide a unique approach to investigate the feasibility of humanized monoclonal antibody imaging in atherosclerotic disease in vivo. The biodistribution of bevacizumab in mice was earlier investigated by our group and showed a low muscle accumulation of the tracer, which is a promising property for imaging carotid arteries and could offer the opportunity to depict lesions with a high target to muscle ratio. 3 Additionally, in a clinical study by our group, accumulation of 89 Zr-bevacizumab was calculated in different organs in patients with renal cell carcinoma. 22 The mean specific uptake value of 89 Zrbevacizumab in human muscle tissue was 0.47 6 0.15% injected dose per gram, which makes the tracer a promising probe for imaging carotid arteries in humans due to low tracer uptake in surrounding muscle tissue.
The current study provides evidence that bevacizumab imaging for the depiction of tissue abundance of VEGF in atherosclerotic plaques is feasible. To expand on observations of this study in human in vivo imaging, blood clearance of the tracer should be measured and dosimetry should be performed to provide further information on the potential of 89 Zr-bevacizumab application in a clinical setting. Moreover, due to the high radiation burden associated with 89 Zr-labeled probes, it seems reasonable to label VEGF-targeted probes with isotopes with a shorter half-life and lower radiation energy such as 18 F to impose less radiation burden to patients undergoing imaging. Bevacizumab is not feasible to carry PET tracers with a shorter half-life because of its long biologic half-life. Future pilot studies on in vivo imaging of radiolabeled or fluorescent VEGF-targeted probes can provide further information on the potential of bevacizumab radionuclide imaging in cardiovascular diseases.
It could also be of interest to use radiolabeled ranibizumab, a monoclonal antibody fragment derivative of bevacizumab that has a serum half-life of 2 to 6 hours, for the detection of VEGF signaling in human plaques. The latter could be clinically more favorable as 89 Zr-bevacizumab takes at least 2 to 3 days before imaging and is associated with an unacceptable high radiation burden. In a recent study on mouse xenograft models of human cancer, it was shown that 89 Zr-ranibizumab-PET allows rapid visualization of VEGF with high affinity to all VEGF-A isoforms. 23 Rapid blood clearance and maximal tumor uptake within 24 hours make ranibizumab a promising tracer for future human studies. Theoretically, 18 F-labeled ranibizumab would result in more optimal tracer kinetics and a large decrease in the radiation burden because the radiation burden associated with 89 Zrlabeled probes is too high.
In addition to the use of radiolabeled bevacizumab, the use of targeted fluorescent imaging could be of interest for imaging VEGF in atherosclerotic plaques. In a recent study, we demonstrated that IRDye 800CW-labeled bevacizumab showed a high specificity and sensitivity in detecting VEGF in tumor models in vivo. 24 The possibility to detect submillimeter lesions with an intraoperative near-infrared camera matches the structural characteristics of carotid atherosclerosis. Moreover, anatomic exteriority of carotid artery provides the opportunity to overcome the drawback of fluorescent imaging in lack of penetration.
Conclusion
This study illustrates the potential of VEGF as a target for visualization of pathobiologic processes in the development of atherosclerosis. Specifically, heterogeneous 89 Zrbevacizumab uptake within plaques was observed. Noninvasive imaging of VEGF could provide clinicians with a new and perhaps better tool in the determination of individuals with a higher risk of cardiovascular events.
